P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

• H. Quach,
• X. Leleu,
• M.-V. Mateos,
• S. Z. Usmani,
• A. K. Nooka,
• A. Goldrick,
• R. Najdi,
• N. Shu,
• T. Facon

Affiliations

H. Quach

1 University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia

X. Leleu

2 CHU de Poitiers, La Miletrie/INSERM CIC 1402, Poitiers, France

M.-V. Mateos

3 University Hospital Salamanca/ISAL, Salamanca, Spain

S. Z. Usmani

4 Memorial Sloan Kettering Cancer Center, New York

A. K. Nooka

5 Winship Cancer Institute, Emory University, Atlanta

A. Goldrick

6 Amgen, Thousand Oaks, United States of America

R. Najdi

6 Amgen, Thousand Oaks, United States of America

N. Shu

7 Parexel, Chengdu, China

T. Facon

8 Hôpital Claude Huriez, Lille, France